Skip to content
GERICLINICS

GeriQBank · Paper III · Q4

Drug holiday

Moderate YieldAsked ×17-mark note
Topic
Prescribing & Polypharmacy
Chapter
Pharmacotherapy & Perioperative Medicine
Years asked
Not recorded in the source
Frequency
Set 1× in Paper III (2009–2025)

As set in the university paper

  • Drug holiday.

    Paper III · Pharmacology, Prescribing & Perioperative Care · asked ×1 · 7-mark note · see in paper list

Detailed answer

Pro · free in beta
Attempt it firstOutline your answer as a 7-mark note before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer

High-yield points

1.

Definition. A drug holiday is a planned, temporary, supervised interruption of a drug in a patient who is expected to resume it, undertaken for a defined purpose and with a defined monitoring plan.

2.

Distinguish it from three other things. It is not deprescribing (which is intended to be permanent), not non-adherence (which is unplanned), and not a dose reduction (the drug is stopped completely for a period).

3.

Purposes. (i) To reduce cumulative toxicity from long-term exposure; (ii) to test whether the drug is still needed; (iii) to unmask an adverse effect wrongly attributed to disease; (iv) to allow recovery of receptor sensitivity or tolerance; (v) to permit a procedure or investigation.

4.

The principal current indication is the bisphosphonate drug holiday. Bisphosphonates are retained in bone with a long terminal half-life, so anti-fracture protection persists after stopping, while the rare harms of prolonged use — atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ) — are exposure-dependent.

5.

Practical bisphosphonate rule. Reassess fracture risk after 5 years of oral or 3 years of intravenous therapy. If risk is low to moderate (no prior hip/vertebral fracture, hip T-score better than −2.5), offer a holiday of about 2–3 years. If risk remains high, continue to 10 years oral / 6 years intravenous. Restart if BMD falls significantly, bone turnover markers rise, or a fracture occurs.

6.

Critical exception — denosumab. A drug holiday must never be taken with denosumab: cessation causes rebound bone loss with multiple vertebral fractures. Denosumab must always be followed by a bisphosphonate or another antiresorptive.

7.

Other situations where the term is used. Gradual dose reduction and trial withdrawal of antipsychotics in dementia and of benzodiazepines/hypnotics; brief withdrawal of a statin to test whether myalgia is drug-related; periprocedural interruption of anticoagulants and antiplatelets; and short interruptions of some immunosuppressants and stimulants.

8.

An abandoned practice worth knowing. The levodopa drug holiday in Parkinson's disease, once used to restore responsiveness, is now contraindicated because abrupt withdrawal precipitates a neuroleptic-malignant-like syndrome, aspiration, deep vein thrombosis and death.

9.

Risks of any drug holiday: relapse of the treated disease, drug withdrawal syndromes, patient confusion about whether to restart, and being lost to follow-up so that the "holiday" silently becomes permanent.

10.

Good practice. Document the indication, the planned duration, the monitoring plan and the criteria for restarting in the notes and in the patient's own record; agree it with the patient and family; and set a review appointment before the holiday begins.

Latest Updates (2023–Present) — three points

Duration is drug-specific, not one-size-fits-all. The offset of effect differs between agents: alendronate has the longest residual protection, risedronate the shortest (holiday of ~1–2 years, with reassessment before 2 years), and zoledronic acid an intermediate 3–5 years. A large Ontario cohort found a higher hip fracture risk after 2 years off risedronate than off alendronate (Annals of Internal Medicine).

Individualisation is now the stated standard. Commentaries and reviews (J Clin Endocrinol Metab, 2024–2025; Current Osteoporosis Reports, 2025–2026) conclude that holiday duration must be modified by total prior bisphosphonate exposure, agent used, hip BMD, falls risk, sex and body weight — "one size does not fit all". AFF risk falls rapidly (~72% per year) after stopping.

Very old and very-high-risk patients are increasingly advised not to take a holiday at all, because absolute hip fracture risk far exceeds the very low AFF risk (AFF accounts for fewer than 5 per 1000 hip fractures). ACP's living guideline and ACOG (2023) accept a holiday of 2–4 years but only after risk reassessment.

Current Practice Update

Textbook position (Essentials 7th ed.) Current evidence and practice (2023–2026) "The ultimate duration of bisphosphonate therapy is still not This remains directionally correct but is now operationalised: formal established... for many patients 3 to 5 years of treatment reassessment at 5 years oral / 3 years IV, holiday only for low-to-may suffice, but those at highest risk (including older moderate risk, continuation to 10 years oral / 6 years IV in high risk, with patients) may benefit from longer treatment." explicit restart criteria.

Drug withdrawal is discussed generically under The drug holiday is now a distinct, protocolised concept with defined deprescribing and tapering, without a structured "drug duration and restart rules, most fully developed for bisphosphonates and holiday" framework. applied cautiously to antipsychotics and hypnotics.

Denosumab discussed as an antiresorptive option without a Absolute contraindication to a holiday — rebound vertebral fracture risk stopping rule. mandates sequential antiresorptive therapy after stopping.

Examiner's Tip

Open with the one-line definition and immediately separate it from deprescribing — "planned and temporary, with the intention to resume."

State the numbers: "5 years oral, 3 years intravenous, then reassess; holiday 2–3 years in low risk; continue to 10 years oral / 6 years IV in high risk."

Never omit: "A drug holiday is contraindicated with denosumab because of rebound vertebral fractures." Mention the levodopa drug holiday as an abandoned and dangerous practice — this shows historical depth and is a common viva follow-up.

How was your recall?

Rating marks the question complete. “Need another pass” also adds it to your bookmarks.

References

Spotted an error or something out of date?Report a problem with this page